New in @JAMAOnc: We compared the AQUILA trial criteria vs the 2/20/20 model in two SMM cohorts.
• 2/20/20 identified fewer as high-risk with 44% progression risk at 2 yrs
• AQUILA labels ~3× more as high-risk, 27% progressed at 2 yrs jamanetwork.com/journals/jamao… #mmsm @sykristinsson
• 2/20/20 identified fewer as high-risk with 44% progression risk at 2 yrs
• AQUILA labels ~3× more as high-risk, 27% progressed at 2 yrs jamanetwork.com/journals/jamao… #mmsm @sykristinsson